PROGRESSION-FREE SURVIVAL IS A ROBUST SURROGATE ENDPOINT OF OVERALL SURVIVAL IN IMMUNOTHERAPY TRIALS OF HEPATOCELLULAR CARCINOMA

被引：0
|
作者：
Cabibbo, Giuseppe [1 ]
Celsa, Ciro [2 ,3 ]
Enea, Marco [2 ]
Battaglia, Salvatore [2 ]
Rizzo, Giacomo [2 ]
Busacca, Anita [2 ]
Matranga, Domenica [2 ]
Attanasio, Massimo [2 ]
Reig, Maria [4 ]
Craxi, Antonio [5 ]
Camma, Calogero [3 ]
机构：
[1] Univ Palermo, Dipartimento Biomed Med & Interne Specialist Di B, Sez Gastroenterol & Epatol, Palermo, Italy
[2] Univ Palermo, Palermo, Italy
[3] Univ Palermo, Sect Gastroenterol & Hepatol, Dipartimento Promoz Salute Materno Infantile Med, Palermo, Italy
[4] Univ Barcelona, Hosp Clin, Barcelona Clin Liver Canc BCLC Grp, Liver Unit,Idibaps,Ciberehd, Barcelona, Spain
[5] Univ Palermo, Dibimis, Gastroenterolgy & Liver Unit, Palermo, Italy
来源：
HEPATOLOGY | 2020年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1068
引用
收藏
页码：649A / 649A
页数：1
相关论文
共 50 条
  • [41] THE VALUE OF PROGRESSION-FREE SURVIVAL (PFS) AS AN ENDPOINT IN ONCOLOGY TRIALS
    Quinn, C.
    Palmer, S.
    Bruns, J.
    Grant, C.
    Sykes, D.
    Kaura, S.
    VALUE IN HEALTH, 2015, 18 (07) : A684 - A685
  • [42] The validity of progression-free survival (PFS) 2 as a surrogate endpoint for overall survival (OS) in randomized controlled trials (RCTs) of advanced solid tumors.
    Woodford, Rachel
    Zhou, Deborah
    Kok, Peey-Sei
    Lord, Sally
    Marschner, Ian
    Friedlander, Michael
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Comment on: Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors
    Schoenfeld, David A.
    DRUGS, 2017, 77 (10) : 1137 - 1138
  • [44] Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis
    Paoletti, Xavier
    Oba, Koji
    Bang, Yung-Jue
    Bleiberg, Harry
    Boku, Narikazu
    Bouche, Olivier
    Catalano, Paul
    Fuse, Nozomu
    Michiels, Stefan
    Moehler, Markus
    Morita, Satoshi
    Ohashi, Yasuo
    Ohtsu, Atsushi
    Roth, Arnaud
    Rougier, Philippe
    Sakamoto, Junichi
    Sargent, Daniel
    Sasako, Mitsuru
    Shitara, Kohei
    Thuss-Patience, Peter
    Van Cutsem, Eric
    Burzykowski, Tomasz
    Buyse, Marc
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (21): : 1667 - 1670
  • [45] Comment on: Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors
    David A. Schoenfeld
    Drugs, 2017, 77 : 1137 - 1138
  • [46] Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.
    Halabi, Susan
    Roy, Akash
    Yang, Qian
    Xie, Wanling
    Kelly, William Kevin
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Getting it first versus getting it right: weighing the value of and evidence for progression-free survival as a surrogate endpoint for overall survival in glioblastoma
    Alexander, Brian M.
    Trippa, Lorenzo
    NEURO-ONCOLOGY, 2015, 17 (05) : 765 - 766
  • [48] Evaluation of progression-free survival as a surrogate endpoint for overall survival in locally advanced or metastatic differentiated thyroid cancer: a systematic review
    Yang, Shijie
    Zhan, Jing
    Xu, Xiequn
    ENDOCRINE, 2023, 82 (03) : 491 - 497
  • [49] Evaluation of progression-free survival as a surrogate endpoint for overall survival in locally advanced or metastatic differentiated thyroid cancer: a systematic review
    Shijie Yang
    Jing Zhan
    Xiequn Xu
    Endocrine, 2023, 82 : 491 - 497
  • [50] Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer
    Hughes, Michael D.
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2008, 17 (05) : 487 - 495
12345